Adaptimmune, Cell & Gene On COVID-19's Impact On The Cell And Gene Sector
By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1
In this video, Michael Blackton, VP QA CMC and John Lunger Chief Patient Supply Officer at Adaptimmune talked to Cell & Gene’s Chief Editor, Erin Harris, about COVID-19’s impact on the cell and gene sector.
Adaptimmune is an autologous cell therapy company that develops novel cell therapies for people with cancer. You’ll see them discuss how COVID-19 has impacted the cell and gene sector to date and how the sector responded to the pandemic. They discussed the sector before COVID-19 and what “the after” looks like for CGTs. And, of course, what this pandemic means for the patient.
This website uses cookies to ensure you get the best experience on our website. Learn more